HDFC Pharma and Healthcare Fund
The scheme seeks to provide long-term capital appreciation by investing predominantly in equity and equity related securities of Pharma and healthcare companies.
Growthvine rating: 3/5 — ranked #23 of 85 in category.
Fund basics
| Category | Equity: Sectoral |
|---|
| NAV | ₹21.21 (as of 2026-10-01) |
|---|
| AUM | ₹3,311 Cr |
|---|
| Expense ratio | 1.66% |
|---|
| Riskometer | Very High |
|---|
| Fund manager | Nikhil Mathur |
|---|
| Exit load | 1% for redemption within 30 days |
|---|
Performance & risk
| Standard deviation | 0.00% |
|---|
| Max drawdown | −15.07% |
|---|
| Alpha | 0 |
|---|
| Beta | 0 |
|---|
Over 5 years, captured 105.5% of NIFTY Pharma's upside and 74.1% of its downside.
Market cap allocation
| Large cap | 28.3% |
|---|
| Mid cap | 33.7% |
|---|
| Small cap | 38.0% |
|---|
Concentration
| Top 5 holdings | 30.7% |
|---|
| Top 10 holdings | 48.9% |
|---|
| Total holdings | 39 |
|---|
Top holdings
- Divis Laboratories Ltd. — 9.5%
- Sun Pharmaceutical Industries Ltd. — 8.9%
- Torrent Pharmaceuticals Ltd. — 4.1%
- Max Healthcare Institute Limited — 4.1%
- Lupin Ltd — 4.0%
- Cipla Ltd. — 3.9%
- Aster DM Healthcare Limited — 3.8%
- Neuland Laboratories Limited. — 3.7%
- Anthem Biosciences Limited — 3.5%
- ACUTAAS CHEMICALS LIMITED — 3.2%
Top sectors
- Pharma & Biotech — 72.1%
- Healthcare — 26.3%
- Cash — 1.6%
Calendar-year track record
| Year | Return | Quartile | Category rank |
|---|
| 2026 (partial) | 23.1% | Q1 (Top) | #2 of 76 |
| 2025 | 1.2% | Q2 | #29 of 69 |
| 2024 | 50.3% | Q1 (Top) | #1 of 58 |